ACQUIRED NEUROPATHIES: FROM CLASSIFICATION TO CLINICAL MANAGEMENT AND INVESTIGATION TECHNIQUES

Acquired neuropathies encompass a diverse group of disorders affecting the peripheral nervous system, which includes all nerves outside the brain and spinal cord. Unlike inherited neuropathies, these conditions develop during an individual’s lifetime, often as a result of systemic diseases, toxins, infections, or immune dysregulation. Understanding their classification, clinical presentation, diagnostic pathways, and management strategies is crucial for effective patient care, given their potential to cause significant disability and impact quality of life.

Introduction to Acquired Neuropathies

The peripheral nervous system (PNS) transmits signals between the central nervous system (CNS) and the rest of the body, controlling motor functions, sensation, and autonomic processes. Damage to these nerves, known as neuropathy, can impair communication, leading to a wide array of symptoms. Acquired neuropathies are a common neurological problem, with prevalence rates varying significantly depending on the underlying cause, but generally increasing with age. They represent a diagnostic and therapeutic challenge due to their heterogeneous nature, necessitating a structured approach to diagnosis and management.

Classification of Acquired Neuropathies

Acquired neuropathies can be classified based on several criteria, including the predominant nerve fiber affected, the distribution of symptoms, the pathological mechanism, and, most importantly, their etiology.

A. By Predominant Nerve Fiber Involvement:

1. Motor Neuropathy: Primarily affects motor nerves, leading to weakness, muscle atrophy, and cramps.
2. Sensory Neuropathy: Primarily affects sensory nerves, causing numbness, tingling, burning pain, and loss of sensation (e.g., proprioception, vibration, touch).
3. Autonomic Neuropathy: Affects autonomic nerves, leading to dysfunction in bodily processes such as heart rate, blood pressure, digestion, and bladder control.
4. Sensorimotor Neuropathy: Most common type, affecting both motor and sensory nerves.
5. Small Fiber Neuropathy: Affects thinly myelinated Aδ-fibers and unmyelinated C-fibers, responsible for pain and temperature sensation. Often presents with burning pain, allodynia, and autonomic symptoms, with normal routine nerve conduction studies.

B. By Distribution:

1. Polyneuropathy: The most common pattern, characterized by symmetrical, generalized involvement of peripheral nerves, typically starting distally in the longest nerves (e.g., feet then hands – “stocking-glove” distribution).
2. Mononeuropathy: Involvement of a single peripheral nerve, often due to compression, entrapment, or trauma (e.g., Carpal Tunnel Syndrome, ulnar neuropathy).
3. Mononeuropathy Multiplex: Asymmetrical, stepwise involvement of two or more discrete peripheral nerves in different parts of the body (e.g., vasculitic neuropathy, multifocal motor neuropathy).
4. Radiculopathy/Plexopathy: Involvement of nerve roots (radiculopathy) or nerve plexuses (brachial or lumbosacral plexopathy), though strictly speaking, these are not always classified as “peripheral neuropathies” in the narrowest sense, they are often considered in the differential diagnosis of peripheral nerve disorders.

C. By Temporal Course:

1. Acute: Symptoms develop rapidly over days to four weeks (e.g., Guillain-Barré Syndrome).
2. Subacute: Symptoms develop over four to eight weeks.
3. Chronic: Symptoms develop gradually over more than eight weeks, often insidiously (e.g., Chronic Inflammatory Demyelinating Polyneuropathy, diabetic neuropathy).

D. By Pathological Mechanism (Electrophysiological Classification):

1. Demyelinating Neuropathy: Damage to the myelin sheath, slowing nerve conduction velocity (NCS shows reduced velocities, prolonged latencies, conduction block, temporal dispersion). Axons are relatively spared initially.
2. Axonal Neuropathy: Damage to the nerve axon itself, leading to Wallerian degeneration distal to the injury (NCS shows reduced amplitudes). Myelin may secondarily degenerate.
3. Mixed Demyelinating-Axonal Neuropathy: Features of both.

E. By Etiology (Most Clinically Relevant Classification):

1. Inflammatory/Immune-mediated Neuropathies:
   • Guillain-Barré Syndrome (GBS): An acute, usually post-infectious, immune-mediated demyelinating polyneuropathy (AIDP is the most common form; axonal variants like AMAN and AMSAN exist). Characterized by rapidly progressive, ascending weakness and areflexia.
   • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A chronic, often relapsing/remitting or progressive, immune-mediated demyelinating polyneuropathy with symmetrical weakness and sensory loss.
   • Multifocal Motor Neuropathy (MMN): A rare, chronic, immune-mediated neuropathy characterized by slowly progressive, asymmetrical weakness without significant sensory loss, often with conduction block.
   • Vasculitic Neuropathy: Neuropathy secondary to inflammation and damage of the vasa nervorum (blood vessels supplying nerves), often presenting as a painful mononeuropathy multiplex. Can be associated with systemic vasculitides (e.g., Polyarteritis Nodosa, Granulomatosis with Polyangiitis).
   • Paraprotein-associated Neuropathies: Neuropathies associated with monoclonal gammopathies of undetermined significance (MGUS), multiple myeloma, POEMS syndrome, or amyloidosis. Can be demyelinating or axonal.
   • Sarcoidosis-associated Neuropathy: Can manifest as various patterns of neuropathy.
2. Metabolic/Nutritional Neuropathies:
   • Diabetic Neuropathy: The most common acquired neuropathy, manifesting as symmetrical distal sensorimotor polyneuropathy, autonomic neuropathy, mononeuropathies, or radiculoplexus neuropathy (diabetic amyotrophy).
   • Uremic Neuropathy: Occurs in chronic kidney failure, typically a distal, symmetrical sensorimotor polyneuropathy.
   • Thyroid Dysfunction: Both hypothyroidism and hyperthyroidism can cause neuropathy.
   • Vitamin Deficiencies: B1 (thiamine), B6 (pyridoxine), B12 (cobalamin), E. Deficiencies often cause axonal sensorimotor polyneuropathies.
   • Vitamin B6 Toxicity: Paradoxically, high doses of pyridoxine can cause sensory neuropathy.
3. Toxic Neuropathies:
   • Alcoholic Neuropathy: Common, typically a distal, symmetrical, axonal sensorimotor polyneuropathy, often compounded by nutritional deficiencies.
   • Chemotherapy-induced Peripheral Neuropathy (CIPN): A significant side effect of many chemotherapeutic agents (e.g., platinum compounds, taxanes, vinca alkaloids), usually causing a painful, dose-dependent sensory neuropathy.
   • Drug-induced Neuropathies: Various medications (e.g., isoniazid, amiodarone, metronidazole, statins, nitrofurantoin).
   • Heavy Metal Toxicity: Lead, mercury, arsenic, thallium.
   • Industrial Toxins: Organic solvents (e.g., n-hexane).
4. Infectious Neuropathies:
   • HIV-associated Neuropathy: Can manifest in various forms, including distal symmetrical polyneuropathy, GBS, or mononeuropathy multiplex.
   • Lyme Disease: Can cause radiculopathy, mononeuropathy multiplex, or GBS-like syndromes.
   • Leprosy: Causes chronic, focal, demyelinating neuropathy with loss of pain and temperature sensation, often in cool areas of the body.
   • Diphtheritic Neuropathy: Often involves cranial nerves and later a generalized polyneuropathy.
   • Herpes Viruses (VZV, HSV, CMV): Can cause radiculopathies, mononeuropathies, or GBS.
5. Critical Illness Neuropathy and Myopathy:
   • Often seen in mechanically ventilated patients in intensive care units, causing profound weakness and difficulty weaning from the ventilator. Typically axonal.
6. Cancer-related Neuropathies:
   • Paraneoplastic Neuropathies: Immune-mediated neuropathies associated with underlying malignancy (e.g., sensory neuronopathy with small cell lung cancer, Lambert-Eaton Myasthenic Syndrome).
   • Direct Infiltration/Compression: Less common, but cancer can directly infiltrate nerve plexuses.

Clinical Features

The clinical presentation of acquired neuropathies is highly variable, depending on the type of nerve fibers involved, distribution, and underlying cause.

A. General Symptoms and Signs:

• Sensory Symptoms: Numbness, tingling (paresthesias), burning or shooting pain (dysesthesias), heightened sensitivity (allodynia, hyperalgesia), loss of sensation (touch, vibration, proprioception, temperature).
• Motor Symptoms: Weakness, muscle cramps, muscle twitching (fasciculations), muscle atrophy, difficulty with fine motor tasks, gait instability, foot drop.
• Autonomic Symptoms: Orthostatic hypotension (dizziness upon standing), abnormal sweating, dry eyes/mouth, gastrointestinal motility issues (constipation, diarrhea), bladder dysfunction (urinary retention), erectile dysfunction.
• Deep Tendon Reflexes: Often reduced or absent, especially in demyelinating neuropathies.

B. Pattern Recognition:

• Distal Symmetrical Polyneuropathy: Most common pattern. Starts in the toes/feet, then ascends. Later involves fingers/hands. Sensory loss in a “stocking-glove” distribution. Weakness is typically distal. Diabetes, alcohol, uremia are common causes.
• Mononeuropathy: Symptoms confined to the distribution of a single nerve (e.g., numbness and tingling in the thumb, index, and middle fingers for Carpal Tunnel Syndrome).
• Mononeuropathy Multiplex: Painful, asymmetrical, stepwise onset of symptoms in multiple, discrete nerve distributions. Highly suggestive of vasculitis, sarcoidosis, or multifocal inflammatory conditions.
• Acute Ascending Weakness: Rapidly progressive weakness, often starting in legs and ascending to trunk, arms, and even bulbar muscles, accompanied by areflexia. Characteristic of GBS.
• Chronic Progressive/Relapsing Weakness: Symmetrical weakness and sensory loss, with diminished reflexes, progressing over months or years. Suggestive of CIDP.
• Predominant Motor Weakness with Conduction Block: Asymmetrical, insidious weakness without significant sensory loss. MMN.
• Small Fiber Neuropathy: Burning pain, paresthesias, and autonomic symptoms, often with normal strength and reflexes.

Investigations

A thorough diagnostic workup is essential to identify the specific type and etiology of acquired neuropathy, guiding appropriate management.

A. History and Physical Examination:

• Detailed History: Onset, progression, types of symptoms (sensory, motor, autonomic), associated medical conditions (diabetes, kidney disease, autoimmune disorders), alcohol use, medication history, exposure to toxins, family history (to rule out inherited forms).
• Neurological Examination: Assessment of mental status, cranial nerves, motor strength, muscle tone, bulk, reflexes, and all modalities of sensation. Gait and balance assessment.

B. Laboratory Tests:

• Routine Blood Work: Complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood glucose/HbA1c (for diabetes), renal and liver function tests, thyroid function tests.
• Vitamin Levels: B1, B6, B12, E.
• Autoimmune Markers: Antinuclear antibody (ANA), rheumatoid factor (RF), extractable nuclear antigens (ENA panel) for connective tissue diseases; anti-neutrophil cytoplasmic antibodies (ANCA) for vasculitis.
• Infectious Screening: HIV serology, Lyme serology, hepatitis panel, syphilis serology.
• Monoclonal Gammopathy Screening: Serum and urine protein electrophoresis with immunofixation to detect paraproteins (MGUS, myeloma, amyloidosis).
• CSF Analysis: Lumbar puncture to examine cerebrospinal fluid. In GBS and CIDP, albuminocytological dissociation (elevated protein with normal cell count) is characteristic.

C. Electrophysiological Studies (Nerve Conduction Studies – NCS and Electromyography – EMG):

• Gold Standard: These studies are crucial for confirming the presence of neuropathy, classifying it (axonal vs. demyelinating), determining distribution (focal vs. generalized), and assessing severity.
• NCS: Involves stimulating nerves and recording responses from muscles or sensory nerves. Measures nerve conduction velocity, amplitude (nerve or muscle response), and latency.
  • Demyelinating: Characterized by slowed conduction velocities, prolonged latencies, temporal dispersion, and conduction block.
  • Axonal: Characterized by reduced amplitudes with relatively preserved conduction velocities and latencies (until severe axonal loss).
• EMG: Involves inserting a needle electrode into muscles to assess electrical activity at rest and during voluntary contraction. Helps differentiate primary muscle disorders from neuropathies, identify denervation and reinnervation, and assess chronicity.

D. Nerve Biopsy:

• Reserved for specific cases where routine investigations are inconclusive, particularly when vasculitis, amyloidosis, sarcoidosis, or leprosy are suspected. Sural nerve is commonly biopsied. Provides histological evidence of inflammation, amyloid deposits, or specific pathological changes.

E. Imaging:

• MRI (Magnetic Resonance Imaging): Of the spine, brachial plexus, or lumbosacral plexus may be used to rule out compressive lesions (e.g., disc herniation, tumors) or inflammatory processes directly affecting nerve roots or plexuses.
• Ultrasound: Can visualize nerve swelling or compression in some cases.

F. Genetic Testing:

• Primarily for inherited neuropathies, but may be considered in atypical or refractory cases where an acquired cause remains elusive, especially in children or young adults.

Management

Management of acquired neuropathies is multifaceted, focusing on treating the underlying cause, alleviating symptoms, preventing complications, and facilitating functional recovery through rehabilitation.

A. Treatment of the Underlying Cause: This is the most critical aspect of management.

• Inflammatory/Immune-mediated Neuropathies:
  • GBS: Intravenous Immunoglobulin (IVIG) or Plasma Exchange (PE) are first-line treatments to modulate the immune response. Early initiation is crucial.
  • CIDP: Corticosteroids (e.g., prednisone), IVIG, or PE are standard. Maintenance therapy with immunosuppressants (e.g., azathioprine, mycophenolate mofetil) or other immunomodulators (e.g., rituximab) may be required for chronic forms.
  • MMN: Responds specifically to high-dose IVIG. Corticosteroids and PE are generally ineffective.
  • Vasculitic Neuropathy: High-dose corticosteroids (e.g., prednisone) combined with immunosuppressants (e.g., cyclophosphamide, rituximab) for severe, progressive cases.
  • Paraprotein-associated Neuropathies: Treatment is directed at the underlying monoclonal gammopathy or myeloma (chemotherapy, stem cell transplantation).
• Metabolic/Nutritional Neuropathies:
  • Diabetic Neuropathy: Strict glycemic control is paramount to prevent progression.
  • Uremic Neuropathy: Dialysis or kidney transplantation.
  • Vitamin Deficiencies: Appropriate vitamin supplementation.
• Toxic Neuropathies:
  • Removal of the offending agent: Discontinuation of neurotoxic drugs, avoidance of alcohol or industrial toxins.
  • Chelation therapy: For certain heavy metal poisonings.
• Infectious Neuropathies:
  • Antimicrobials: Antibiotics for Lyme disease, leprosy; antivirals for herpes viruses.

B. Symptomatic Management:

• Neuropathic Pain: Often debilitating. Medications include gabapentin, pregabalin (antiepileptics), tricyclic antidepressants (TCAs like amitriptyline), serotonin-norepinephrine reuptake inhibitors (SNRIs like duloxetine, venlafaxine), and topical agents (lidocaine patches, capsaicin cream). Opioids are generally reserved for severe, refractory pain due to addiction potential.
• Weakness: Physical therapy to maintain muscle strength, prevent contractures, and improve mobility. Occupational therapy for adaptive strategies and assistive devices. Assistive devices (e.g., ankle-foot orthoses for foot drop, canes, walkers) may be needed.
• Autonomic Dysfunction:
  • Orthostatic Hypotension: Education, increased fluid and salt intake, compression stockings, medications like fludrocortisone or midodrine.
  • Gastrointestinal Symptoms: Dietary modifications, pro-motility agents, anti-diarrheals/laxatives as needed.
  • Bladder Dysfunction: Scheduled voiding, medications, or self-catheterization if severe.
• Foot Care: Meticulous skin care and regular podiatric evaluation for patients with sensory loss, especially those with diabetes, to prevent ulcers and infections.

C. Rehabilitation:

• Physical Therapy: Focuses on strengthening, balance training, gait training, and preventing muscle atrophy and contractures.
• Occupational Therapy: Helps patients adapt to daily activities, suggests assistive devices, and provides ergonomic advice.
• Speech Therapy: For patients with bulbar weakness (difficulty speaking or swallowing).
• Vocational Rehabilitation: To help individuals return to work or find suitable employment.
• Psychological Support: Counseling and support groups can help patients cope with chronic pain and disability.

Conclusion

Acquired neuropathies are a complex and heterogeneous group of disorders requiring a systematic and comprehensive approach to diagnosis and management. Accurate classification, guided by a detailed history, neurological examination, and targeted investigations, is crucial for identifying the underlying etiology. While treatment of the root cause remains paramount, symptomatic management and rehabilitation play equally vital roles in improving patient outcomes and quality of life. Given the diverse nature of these conditions, a multidisciplinary team approach involving neurologists, pain specialists, physical therapists, occupational therapists, and other specialists is often essential for optimal care. Continued research into the pathogenesis of these neuropathies holds promise for developing more targeted and effective therapies in the future.

References:

1. Ropper, A. H., & Samuels, M. A. (2019). Adams and Victor’s Principles of Neurology (11th ed.). McGraw-Hill Education.
2. Saperstein, D. S. (2020). Acquired peripheral neuropathies. Continuum (Minneap Minn), 26(5), 1324-1342.
3. Goldstein, J. M., & Goldstein, J. A. (2018). Peripheral Neuropathy. In Harrison’s Principles of Internal Medicine (20th ed.). McGraw-Hill Education.
4. Hughes, R. A. C., & Cornblath, D. R. (2005). Guillain-Barré syndrome. The Lancet, 366(9479), 1653-1666.
5. Dyck, P. J., & Dyck, P. J. B. (2005). Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology, 65(11), 1698-1707.
6. Kaku, D. A., & Dyck, P. J. (2011). Peripheral Neuropathy. In Bradley’s Neurology in Clinical Practice (6th ed.). Saunders Elsevier.
7. Zis, P., & Hadjivassiliou, M. (2019). Treatment for chronic inflammatory demyelinating polyneuropathy: current perspectives. Journal of Inflammation Research, 12, 173-182.
8. Singleton, J. R., Smith, A. G., & Bromberg, M. B. (2014). Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care, 24(8), 1448-1453.